Discovery Analysis of TCGA Data Reveals Association between Germline Genotype and Survival in Ovarian Cancer Patients

BACKGROUND Ovarian cancer remains a significant public health burden, with the highest mortality rate of all the gynecological cancers. This is attributable to the late stage at which the majority of ovarian cancers are diagnosed, coupled with the low and variable response of advanced tumors to standard chemotherapies. To date, clinically useful predictors of treatment response remain lacking. Identifying the genetic determinants of ovarian cancer survival and treatment response is crucial to the development of prognostic biomarkers and personalized therapies that may improve outcomes for the late-stage patients who comprise the majority of cases. METHODS To identify constitutional genetic variations contributing to ovarian cancer mortality, we systematically investigated associations between germline polymorphisms and ovarian cancer survival using data from The Cancer Genome Atlas Project (TCGA). Using stage-stratified Cox proportional hazards regression, we examined >650,000 SNP loci for association with survival. We additionally examined whether the association of significant SNPs with survival was modified by somatic alterations. RESULTS Germline polymorphisms at rs4934282 (AGAP11/C10orf116) and rs1857623 (DNAH14) were associated with stage-adjusted survival (p= 1.12e-07 and 1.80e-07, FDR q= 1.2e-04 and 2.4e-04, respectively). A third SNP, rs4869 (C10orf116), was additionally identified as significant in the exome sequencing data; it is in near-perfect LD with rs4934282. The associations with survival remained significant when somatic alterations. CONCLUSIONS Discovery analysis of TCGA data reveals germline genetic variations that may play a role in ovarian cancer survival even among late-stage cases. The significant loci are located near genes previously reported as having a possible relationship to platinum and taxol response. Because the variant alleles at the significant loci are common (frequencies for rs4934282 A/C alleles = 0.54/0.46, respectively; rs1857623 A/G alleles = 0.55/0.45, respectively) and germline variants can be assayed noninvasively, our findings provide potential targets for further exploration as prognostic biomarkers and individualized therapies.

[1]  C. Redman,et al.  Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. , 1989, British Journal of Cancer.

[2]  J. Krischer,et al.  BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases , 2005, Cancer.

[3]  A. Berchuck,et al.  Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (OCAC) , 2012, Journal of internal medicine.

[4]  G. Pazour,et al.  Identification of predicted human outer dynein arm genes: candidates for primary ciliary dyskinesia genes , 2005, Journal of Medical Genetics.

[5]  Robert Brown,et al.  Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Benítez,et al.  Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis , 2009, British Journal of Cancer.

[7]  Jinghui Zhang,et al.  Systematic analysis of genetic alterations in tumors using Cancer Genome WorkBench (CGWB). , 2007, Genome research.

[8]  J. Lancaster,et al.  Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin. , 2010, American journal of obstetrics and gynecology.

[9]  M. Nishiyama,et al.  Quantitative prediction of tumor response to neoadjuvant chemotherapy in breast cancer: novel marker genes and prediction model using the expression levels , 2011, Breast Cancer.

[10]  Joe W. Gray,et al.  Genome Wide DNA Copy Number Analysis of Serous Type Ovarian Carcinomas Identifies Genetic Markers Predictive of Clinical Outcome , 2012, PloS one.

[11]  N. Paneth,et al.  Factors associated with small head circumference at birth among infants born before the 28th week. , 2010, American journal of obstetrics and gynecology.

[12]  Xiaoyong Wang.  Fresh platinum complexes with promising antitumor activity. , 2010, Anti-cancer agents in medicinal chemistry.

[13]  E. Gamazon,et al.  Genetic Variation That Predicts Platinum Sensitivity Reveals the Role of miR-193b* in Chemotherapeutic Susceptibility , 2012, Molecular Cancer Therapeutics.

[14]  P. Rose,et al.  Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study. , 2010, Gynecologic oncology.

[15]  Kenneth H. Buetow,et al.  Large-scale analysis of non-synonymous coding region single nucleotide polymorphisms , 2004, Bioinform..

[16]  Yurii S. Aulchenko,et al.  BIOINFORMATICS APPLICATIONS NOTE doi:10.1093/bioinformatics/btm108 Genetics and population analysis GenABEL: an R library for genome-wide association analysis , 2022 .

[17]  Martin Krapcho,et al.  SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .

[18]  David I. Smith,et al.  Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy , 2005, Clinical Cancer Research.

[19]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[20]  G. Mills,et al.  Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer , 2011, Journal of experimental & clinical cancer research : CR.

[21]  D. Hirsch,et al.  Arf and its many interactors. , 2003, Current opinion in cell biology.

[22]  A. W. Prestayko,et al.  Cisplatin (cis-diamminedichloroplatinum II). , 1979, Cancer treatment reviews.

[23]  A. Whittemore,et al.  Common variants at 19p13 are associated with susceptibility to ovarian cancer , 2010, Nature Genetics.

[24]  A. Skubitz,et al.  Differential gene expression identifies subgroups of ovarian carcinoma. , 2006, Translational research : the journal of laboratory and clinical medicine.

[25]  M. Jakupec,et al.  Tumour-inhibiting platinum complexes--state of the art and future perspectives. , 2003, Reviews of physiology, biochemistry and pharmacology.

[26]  Stephen J O'Brien,et al.  Accounting for multiple comparisons in a genome-wide association study (GWAS) , 2010, BMC Genomics.

[27]  K. Matsuo,et al.  Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay , 2010, American journal of clinical oncology.

[28]  Eleazar Eskin,et al.  Rapid and Accurate Multiple Testing Correction and Power Estimation for Millions of Correlated Markers , 2009, PLoS genetics.

[29]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[30]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[31]  D. Harrington.  A class of rank test procedures for censored survival data , 1982 .

[32]  Il-Jin Kim,et al.  Identification of Genes with Differential Expression in Acquired Drug-Resistant Gastric Cancer Cells Using High-Density Oligonucleotide Microarrays , 2004, Clinical Cancer Research.

[33]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[34]  J. Chang-Claude,et al.  Role of genetic polymorphisms and ovarian cancer susceptibility , 2009, Molecular oncology.

[35]  Adrian E. Raftery,et al.  Model-Based Clustering, Discriminant Analysis, and Density Estimation , 2002 .

[36]  Gudmundur A. Thorisson,et al.  The International HapMap Project Web site. , 2005, Genome research.

[37]  H. Kwon,et al.  Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells , 2010, Journal of Cancer Research and Clinical Oncology.

[38]  K. Lange,et al.  Prioritizing GWAS results: A review of statistical methods and recommendations for their application. , 2010, American journal of human genetics.

[39]  S. Seiff.  Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm , 1992 .

[40]  Brooke L. Fridley,et al.  Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients , 2011, Clinical Cancer Research.

[41]  M. Tang,et al.  Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. , 2005, Human reproduction.

[42]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[43]  G. Moreno-Bueno,et al.  Gene expression profiling of breast cancer cells in response to gemcitabine: NF-κB pathway activation as a potential mechanism of resistance , 2007, Breast Cancer Research and Treatment.

[44]  S. Hauptmann,et al.  Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival , 2008, Clinical Cancer Research.

[45]  Jason B. Nikas,et al.  Mathematical Prognostic Biomarker Models for Treatment Response and Survival in Epithelial Ovarian Cancer , 2011, Cancer informatics.

[46]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.